Skip to Content

    Celltrion specializes in “bio­similars”—cheaper generic versions of the pricey “biologic” drugs that are among Big Pharma’s bestsellers. Wall Street analysts project that the firm could achieve up to 25% future annual growth, with sales in multiple markets. U.S. regulators approved this country’s first ­biosimilar in 2015. Since then, Celltrion and its partners have won FDA approval for copies of Johnson & Johnson’s anti-­inflammatory treatment ­Remicade. And in early October, the team got an important preliminary thumbs-up from an FDA advisory panel for a biosimilar version of Roche’s blockbuster cancer drug Rituxan.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score3.6
    Sector
    Health Care
    Industry
    Biotechnology
    CEO
    Woo-Sung Kee
    Websitehttp://www.celltrion.com
    Employees1,218
    HQ Location
    Incheon, South Korea
    Revenues ($M) (Past 12 Months)$925
    Profits ($M) (Past 12 Months)$351
    Market Value as of Oct. 10, 2018 ($M)$31,360